Mizuho Securities Downgrades Valeant Pharmaceuticals (VRX) to Underperform

Mizuho Securities downgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Underperform with a price target of $11.00 (from $25.00).

Analyst Irina Koffler said, "We believe the risk/reward is unfavorable due to growth challenges, 2017 guidance risk, legal overhangs, and weaker asset divestitures. While we see no impending sell catalyst, we believe this stock will edge lower over the next 6-12 months as investor patience wanes. We downgrade to Underperform from Neutral, and lower our PT to $11 from $25."

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $17.83 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades Monster Beverage (MNST) to Neutral, 'Cost Pressures and Weaker Low-end Consumer'
• Teradyne (TER) PT Raised to $125 at TD Cowen
• META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban